[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

Rhea-AI Filing Summary

BeOne Medicines Ltd. insider transaction summary: Principal Accounting Officer Titus B. Ball reported sales on 09/02/2025. The filing shows a disposition of 72,397 Ordinary Shares and a sale of 122 American Depositary Shares at $326.76 per ADS. The filing explains each ADS represents 13 Ordinary Shares and that the ADS sale was executed to satisfy a mandatory tax withholding on vesting restricted share units; those units vest 1/4 on each anniversary of August 31, 2023, subject to continued service. The Form 4 was signed by an attorney-in-fact on 09/04/2025.

Insights

Securities Analyst

TL;DR: Officer sold shares to cover tax withholding on vested RSUs; transaction is routine and non-dilutive.

The Form 4 discloses a disposal of 72,397 ordinary shares and the sale of 122 ADS at $326.76 per ADS, with an explicit statement that the ADS sale satisfied mandatory tax withholding tied to vesting restricted share units. This is a common post-vesting mechanics-driven sale rather than an open-market directional trade. The filing identifies the reporting person as an officer (Principal Accounting Officer), which is relevant for governance transparency. No new options, grants, or unusual derivative activity are reported.

Corporate Governance Expert

TL;DR: Disclosure aligns with Section 16 requirements; sale was for tax withholding related to RSU vesting.

The report includes required detail: relationship to issuer (Officer/Principal Accounting Officer), transaction date, amount sold, and a clear explanation that the ADS sale fulfilled a mandatory withholding obligation under the reporting person’s restricted share unit agreement. The filing was executed via attorney-in-fact and includes the vesting schedule language (one-quarter annually from August 31, 2023). There is no indication of rule 10b5-1 reliance or other trading plan in the text provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ball Titus B.

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares								72,397	D
American Depositary Shares(1)	09/02/2025		S(2)		122	D	$326.76	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each American Depositary Share represents 13 Ordinary Shares.

2. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of August 31, 2023, subject to continued service.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider sold shares in the BeOne Medicines (ONC) Form 4?

The filing reports sales by Titus B. Ball, identified as an officer and Principal Accounting Officer.

How many shares were disposed of according to the Form 4?

The Form 4 shows a disposition of 72,397 Ordinary Shares and a sale of 122 American Depositary Shares.

At what price were the ADS sold in the ONC Form 4?

The 122 ADS were sold at a price of $326.76 per ADS.

Why were the ADS sold according to the filing?

The sale was effected to satisfy a mandatory tax withholding provision under the reporting person’s restricted share unit award agreement in connection with vesting.

What is the ADS to ordinary share conversion disclosed?

The filing states that each American Depositary Share represents 13 Ordinary Shares.

When did the transactions occur and when was the Form 4 signed?

Transactions are dated 09/02/2025, and the Form 4 was signed by an attorney-in-fact on 09/04/2025.